7 Possible Risk Factors for Pulmonary Fibrosis

Prof. Vincent Cottin discusses the diseases which IPF is often confused with. For example, NSIP (non-specific interstitial pneumonia) because of similar imaging and clinical features between both diseases. Read more about idiopathic pulmonary fibrosis here: https://bit.ly/1QiRmr3…

BoehringerUS shared this video where you can see, with a true patient story, how it is to live with idiopathic pulmonary fibrosis (IPF). Watch the video to learn more about it and how pulmonary fibrosis patients caregivers deal with the disease. Learn…

Last week’s hot topic on pulmonary fibrosis was Country Music Star Joe Nichols Shares His Dad’s IPF Story in ‘Breathless,’ a Public Awareness Campaign written by Daniela Semedo. This article was about country music artist Joe Nichols partnering with Boehringer Ingelheim to raise awareness about idiopathic pulmonary…

Combined evidence from the TOMORROW and INPULSIS clinical trials confirms the safety and efficacy of OFEV (nintedanib, Boehringer Ingelheim) in slowing disease progression and greatly reducing acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF), a study reported. The article detailing the pooled analyses of the clinical studies, “…

  Learn more about pulmonary fibrosis here: https://bit.ly/1lfMsiZ   Note: Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always…

A documentary by Jade Cockerill, telling the story of two incredible people who suffer with lung diseases. Ann and Peter Bennett live in Mawnan Smith, Cornwall. Ann suffers with Idiopathic Pulmonary Fibrosis (IPF) a lung disease which has no cure. Even with her illness she has the thrive…

“Professor Vincent Cottin, from National Reference Center for Rare Pulmonary Diseases, Université Claude Bernard Lyon 1, Lyon, discusses why idiopathic pulmonary fibrosis (IPF) is often misdiagnosed.” Read more about idiopathic pulmonary fibrosis: https://bit.ly/1QiRmr3…

Medical device company XENiOS recently announced that it has invested $2.6 million in XOR-Labs Toronto, a spin-off of Toronto General Hospital at University Health Network (UHN), a world-leading center for lung transplantation. The startup company’s organ repair technology has the potential to help thousands of patients suffering from respiratory diseases, including pulmonary…

Redwood City, California-based Third Rock Ventures, LLC, a healthcare venture firm, recently announced $45 million in Series A financing to launch the biotechnology start-up company Pliant Therapeutics, Inc., with a mandate to discover, develop, and commercialize breakthrough drug treatments for fibrotic diseases. Pliant’s product engine has the potential to address the needs…